Trial Profile
A Phase I/II Open-label, Single-arm, Multi-center Study of Ruxolitinib Added to Corticosteroids in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary) ; Calcineurin inhibitors; Corticosteroids
- Indications Graft-versus-host disease
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms REACH4
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 28 Feb 2023 This trial has been completed in Denmark (End Date: 2 Feb 2023) according to European Clinical Trials Database record.
- 15 Feb 2023 This trial has been discontinued in Czech Republic (End Date: 2 Feb 2023) according to European Clinical Trials Database record.
- 14 Feb 2023 Status changed from active, no longer recruiting to completed.